HispanicBusiness

(1) Smith, Ronalde et al. "Reversal of vascular hypertrophy in
hypertensive patients through blockade of angiotensin II receptors. J
Am Soc Hypertension 2008;2(3);165-172
(2) Smith, Ronalde et al. "Reversal of vascular hypertrophy in
hypertensive patients through blockade of angiotensin II receptors. J
Am Soc Hypertension 2008;2(3);165-172
(3) Intengan, HD et al. Resistance Artery Mechanics, Structure, and
Extracellular Components in Spontaneously Hypertensive Rats: Effects
of Angiotensin Receptor Antagonism and Converting Enzyme Inhibition.
Circulation 1999;100;2267-75
(4) Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial
structure and endothelial dysfunction in human essential hypertension
by the angiotensin receptor antagonist losartan. Circulation
2000;101:1653-9.
(5) Schiffrin EL. Vascular and cardiac benefits of angiotensin receptor
blockers. Am J Med 2002;113:409 -18.
(6) Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial
structure and endothelial dysfunction in human essential hypertension
by the angiotensin receptor antagonist losartan. Circulation
2000;101:1653-9.
(7) Mulvany MJ. Effects of angiotensin-converting enzyme inhibition on
vascular remodeling of resistance vessels in hypertensive patients.
Metabolism 1998;47(12 suppl1):S20 -3
(8) Schiffrin EL, Park JB, Pu Q. Effect of crossing over hypertensive
patients from a beta-blocker to an angiotensin receptor antagonist on
resistance artery structure and on endothelial function. J Hypertens
2002;20:71- 8
(9) Thybo NK, Stephens N, Cooper A, Aalkjaer C, Heagerty AM, Mulvany MJ.
Effect of antihypertensive treatment on small arteries of patients
with previously untreated essential hypertension. Hypertension 1995;
25:474-81
(10) Schiffrin EL, Deng LY, Larochelle P. Effects of a beta-blocker or a
converting enzyme inhibitor on resistance arteries in essential
hypertension. Hypertension 1994;23:83-91
(11) Schiffrin EL, Deng LY. Structure and function of resistance arteries
of hypertensive patients treated with a beta-blocker or a calcium
channel antagonist. J Hypertens 1996;14:1247-55
(12) Schiffrin EL. Remodeling of resistance arteries in essential
hypertension and effects of antihypertensive treatment. Am J
Hypertens 2004;17:1192-200
(13) http://www.americanheart.org/presenter.jhtml?identifier=4621 Site
accessed 4/18/2008
(14) High Blood Pressure; Why Should I Care.
http://www.americanheart.org/presenter.jhtml?identifier=2129
Site accessed 6/3/2008
(15) Lewis, EJ. The Role of Angiotensin II Receptor Blockers in Preventing
the Progression of Renal Disease in Patients with Type 2 Diabetes. Am
J Hypertension 2002;15;123S-8S
(16) Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on
renal and cardiovascular outcomes in patients with type 2 diabetes
and nephropathy. N Engl J Med 2001;345:861-9.
(17) Dahlof B, Pennert K, Hansson L. Reversal of left ventricular
hypertrophy in hypertensive patients. A metaanalysis of 109 treatment
studies. Am J Hypertens 1992;5:95-110.
(18) Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity
and mortality in the Losartan Intervention For Endpoint Reduction in
Hypertension Study (LIFE): a randomized trial against atenolol.
Lancet 2002;359:995-1003.
(19) Smith, Ronalde et al. "Reversal of vascular hypertrophy in
hypertensive patients through blockade of angiotensin II receptors. J
Am Soc Hypertension 2008;2(3);165-172
(20) Smith, Ronalde et al. "Reversal of vascular hypertrophy in
hypertensive patients through blockade of angiotensin II receptors. J
Am Soc Hypertension 2008;2(3);165-172
(21) JNC 7 = The Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation and Treatment of High Blood
Pressure (JNC 7), which issued new guidelines in 2003 for
hypertension prevention and management.
(22) Smith, Ronalde et al. "Reversal of vascular hypertrophy in
hypertensive patients through blockade of angiotensin II receptors. J
Am Soc Hypertension 2008;2(3);165-172